Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jutta Beier & Kai M Beeh. (2011) Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 237-243.
Read now
Read now
Paschalis Steiropoulos, Argyris Tzouvelekis & Demosthenes Bouros. (2008) Formoterol in the management of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 3:2, pages 205-216.
Read now
Read now
Articles from other publishers (20)
Stefano Nardini, Gianna Camiciottoli, Salvatore Locicero, Rosario Maselli, Franco Pasqua, Giovanni Passalacqua, Riccardo Pela, Alberto Pesci, Alfredo Sebastiani & Alessandro Vatrella. (2014) COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Dave Singh, Gabriele Nicolini, Eddi Bindi, Massimo Corradi, Daniele Guastalla, Jorg Kampschulte, Władysław Pierzchała, Abdullah Sayiner, Mária Szilasi, Claudio Terzano & Jørgen Vestbo. (2014) Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Anke J.M.C. LahaijeYvonne F. HeijdraLaura M. WillemsHanneke A.C. van HelvoortP.N. Richard Dekhuijzen. (2012) COPD Anno 2011: Emphasis on Bronch(iol)odilation. Journal of Aerosol Medicine and Pulmonary Drug Delivery 25:3, pages 148-153.
Crossref
Crossref
Mario Cazzola, Pierluigi Paggiaro, Paolo Palange, Leif Bjermer, Pilar Ausin, Lars-Goran Carlsson, Jan Ekelund & Jan Lotvall. (2012) Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation 32:3, pages 147-155.
Crossref
Crossref
Miron A Bogdan, Hisamichi Aizawa, Yoshinosuke Fukuchi, Michiaki Mishima, Masaharu Nishimura & Masakazu Ichinose. (2011) Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results. BMC Pulmonary Medicine 11:1.
Crossref
Crossref
Bartolome R. Celli, Donald P. Tashkin, Stephen I. Rennard, Jennifer McElhattan & Ubaldo J. Martin. (2011) Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine 105:8, pages 1176-1188.
Crossref
Crossref
Heinrich Worth, Karin Förster, Göran Eriksson, Ulf Nihlén, Stefan Peterson & Helgo Magnussen. (2010) Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respiratory Medicine 104:10, pages 1450-1459.
Crossref
Crossref
Kai M. Beeh & Jutta Beier. (2010) The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy 27:3, pages 150-159.
Crossref
Crossref
J. Beier, K.-M. Beeh, L. Brookman, G. Peachey, A. Hmissi & S. Pascoe. (2009) Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics 22:6, pages 492-496.
Crossref
Crossref
Claudia Cote, James L. Pearle, Amir Sharafkhaneh & Selwyn Spangenthal. (2009) Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: A multicenter, randomized study. Pulmonary Pharmacology & Therapeutics 22:1, pages 44-49.
Crossref
Crossref
Andrea M Chen, Suzanne G Bollmeier & Patrick M Finnegan. (2008) Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 42:12, pages 1832-1842.
Crossref
Crossref
Adalberto Sperb Rubin, Fábio José Fabrício de Barros Souza, Jorge Lima Hetzel & José da Silva Moreira. (2008) Resposta broncodilatadora imediata ao formoterol em doença pulmonar obstrutiva crônica com pouca reversibilidade. Jornal Brasileiro de Pneumologia 34:6, pages 373-379.
Crossref
Crossref
W.E. Berger & J.A. Nadel. (2008) Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 102:2, pages 173-188.
Crossref
Crossref
Anne LINDBERG, Zsuzsanna SZALAI, Teet PULLERITS & Eva RADECZKY. (2007) Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 12:5, pages 732-739.
Crossref
Crossref
Antonio Anzueto. (2007) Disease Modification in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, pages 609-616.
Crossref
Crossref
Antonio Anzueto. (2006) Clinical Course of Chronic Obstructive Pulmonary Disease: Review of Therapeutic Interventions. The American Journal of Medicine 119:10, pages 46-53.
Crossref
Crossref
Donald P Tashkin. (2005) Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?. Current Opinion in Internal Medicine 4:3, pages 303-310.
Crossref
Crossref
Michael A. Campos & Adam Wanner. (2005) The Rationale for Pharmacologic Therapy in Stable Chronic Obstructive Pulmonary Disease. The American Journal of the Medical Sciences 329:4, pages 181-189.
Crossref
Crossref
Donald P Tashkin. (2005) Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?. Current Opinion in Pulmonary Medicine 11:2, pages 121-128.
Crossref
Crossref
M. Perpiñá Tordera. (2005) ¿Agonistas adrenérgicos β2 de acción prolongada como primera elección?. Archivos de Bronconeumología 41, pages 15-20.
Crossref
Crossref